Yield10 Bioscience reports Q3 EPS (41c), consensus (39c)

Yield10 ended the third quarter of 2023 with $2.8M in unrestricted cash and cash equivalents; a net increase of $0.5M from unrestricted cash and cash equivalents of $2.3M reported as of June 30. “During the third quarter of 2023, we established our “Camelina Seed Genetics to Biofuel” platform as we completed the harvest of spring and winter Camelina and delivered grain to a private biorefining company for processing into biofuel,” said Oliver Peoples, president and CEO of Yield10 Bioscience. “In this harvest cycle, Yield10 and our Camelina growers derived proceeds from the delivery of Camelina grain to our customer. Leveraging our grower network, we also completed a new cycle of Camelina grain contracting for winter 2023/2024. On the business development front, we continue to hold discussions with companies interested in establishing collaborations in biofuels to support the planting of Camelina on large acreage.”